Safety of nevirapine in pregnancy

HIV Medicine

Volumn 8, Issue 1, 2007, Pages 64-69

  Natarajan, Usharani ^a,g   Pym, A ^b   McDonald, C ^c   Velisetty, P ^d   Edwards, S G ^e   Hay, P ^d   Welch, J ^c   de Ruiter, A ^a   Taylor, G P ^f   Anderson, J ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g EAST SURREY HOSPITAL   (United Kingdom)

Author keywords

Cutaneous side effects; Hepatic side effects; Nevirapine; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HELLP SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAUTERINE GROWTH RETARDATION; LIVER FUNCTION TEST; LIVER TOXICITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MATERNAL TREATMENT; PATIENT COMPLIANCE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SUPERINFECTION; THROMBOCYTE COUNT; TOXIC HEPATITIS; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIVER DISEASES; LONDON; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES;

EID: 33846327247     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00433.x     Document Type: Article

References (19)

1. Connor E, Spering R, Gelber R et al. Reduction of maternal infant transmission of HIV-1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-1180.
2. Guay L, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trail. Lancet 1999; 354: 795-802.
3. Taylor GP, Lyall E, Back D, Ward C, Tudor-Williams G. Pharmacological implications of prolonged in utero exposure to nevirapine. Lancet 2000; 355: 2134-2135.
4. Minochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20: 803-805.
5. Hitti J, Frenkel L, Huang S et al. PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36: 772-776.
6. Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected pregnant women: A review of the FDA's adverse event reporting system. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 944].
7. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-1092.
8. Metry DW, Lahart CJ, Farmer KL, Herbert AA. Steven-Johnson syndrome caused by antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44: 354-357.
9. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl. 1): S21-S33.
10. Martinez E, Blanco JL, Arnaiz JA et al. Hepatoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
11. Black M, McKay M, Braude P, Vaughan Jones S, Margesson L. Obstetric and Gynaecologic Dermatology, 2nd edn. Edinburgh, UK: Mosby, 2002.
12. Henson TH, Tuli M, Bushore D, Talanin NY. Recurrent pustular rash in a pregnant woman. Arch Dermatol 2000; 136: 1055-1060.
13. Glanville T, Walker J. HELLP syndrome. The Obstetrician & Gynaecologist 2003; 5: 149-154.
14. Dieterich D, Stern J, Robinson P et al. Analysis of four clinical trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4+ levels, hepatitis B and C seropositivity and baseline liver function tests. 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001 [Abstract 44].
15. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.
16. Mulchahy F, Wallace E, Woods S et al. CD4 counts in pregnancy do not reflect the need for longterm HAART. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 704b].
17. 3 receiving nevirapine (NVP)-containing highly active anti-retroviral therapy (HAART) for the prevention of mother-to-child transmission (PMTCT) in Thailand. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract 322].
18. Thomas T, Amornkul P, Mwidau J et al Preliminary findings: Incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trials using HAART to prevent mother-to-child HIV transmission. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 809].
19. Joao EC, Calvet GA, Menezes JA et al. Nevirapine toxicity in a cohort of HIV-1 infected pregnant women. Am J Obstetrics Gynaecol 2006; 194: 199-202.